Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharm Sci ; 123: 560-568, 2018 Oct 15.
Article in English | MEDLINE | ID: mdl-30081070

ABSTRACT

In this study, a physiologically based pharmacokinetic (PBPK) model was established for valacyclovir based on absolute expression quantity of hPEPT1 along the entire length of the human intestine and other reliable in vitro, in vivo observed data. The PBPK model-3 defined acyclovir as metabolite of valacyclovir and simulated the plasma concentration-time profiles of valacyclovir and acyclovir simultaneously. It was validated strictly by a series of observed plasma concentration-time profiles. The average fold error (AFE) and absolute average fold error (AAFE) values were all smaller than 2. Then, it was used to quantitatively evaluate the effect of hPEPT1, luminal degradation rate, drug release rate and gastric residence time on the oral absorption of valacyclovir and acyclovir. The PBPK model-3 suggests that mainly 75% of valacyclovir was absorbed by active transport of hPEPT1. The luminal degradation of valacyclovir in the upper intestinal lumen cannot be considered the only reason for its incomplete bioavailability. The plasma concentration-time profiles of valacyclovir and its metabolite acyclovir were not sensitive to dissolution rate faster than T85% = 120 min. Prolonged gastric residence time of sustained release tablet can improve the oral absorption of valacyclovir. All in all, the PBPK model-3 in this study is reliable and accurate. It is useful for the research of clinical application and dosage forms design of valacyclovir.


Subject(s)
Acyclovir/pharmacokinetics , Antiviral Agents/pharmacokinetics , Intestinal Absorption , Intestines/enzymology , Models, Biological , Peptide Transporter 1/metabolism , Prodrugs/pharmacokinetics , Valacyclovir/pharmacokinetics , Acyclovir/administration & dosage , Acyclovir/blood , Administration, Oral , Adult , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/blood , Biological Availability , Biotransformation , Delayed-Action Preparations , Drug Liberation , Female , Humans , Hydrolysis , Male , Mice , Prodrugs/administration & dosage , Rats , Reproducibility of Results , Tablets , Valacyclovir/administration & dosage , Valacyclovir/blood
2.
Eur J Drug Metab Pharmacokinet ; 43(6): 693-706, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29748821

ABSTRACT

BACKGROUND AND OBJECTIVES: The helicase-primase inhibitor amenamevir (ASP2151) is a novel therapeutic agent which has been approved for the treatment of herpes zoster. The present study examined the pharmacokinetic profile of amenamevir in rodents and compared it with data from the literature of past and current established therapies (acyclovir and valaciclovir) to provide additional data to facilitate drug discovery and proper drug use. METHODS: In situ absorption, blood and plasma radioactivity concentrations, tissue distribution, and excretion were determined using liquid scintillation counting. Plasma amenamevir concentrations were measured using a validated chromatographic method. Chemical structures of in vivo metabolites were investigated using liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. RESULTS: Amenamevir, after single intravenous administration to mice, had an elimination half-life of 2 h. Bioavailability was 40% after single oral administration. In situ absorption data indicated that amenamevir is mainly absorbed in the small intestine. The main component in mouse plasma was amenamevir, accounting for 87.9% of amenamevir-derived components. Our results suggest that the main elimination pathway in mice is oxidative metabolism at a methyl group and a 1,2,3-trisubstituted benzene ring followed by biliary and fecal excretion. Following oral administration of 14C-amenamevir to mice, 100.63% of the dose (10.06% in urine and 90.46% in feces) was excreted by 96 h post-dose. CONCLUSIONS: The underlying mechanism of the improved pharmacokinetic profile of amenamevir was linked to an improved absorption ratio (not hepatic availability) compared to acyclovir, and qualitative differences in elimination (slow metabolism of amenamevir vs rapid urinary excretion of acyclovir/valaciclovir).


Subject(s)
Acyclovir/pharmacokinetics , Oxadiazoles/pharmacokinetics , Valacyclovir/pharmacokinetics , Acyclovir/blood , Animals , Biological Availability , Carbon Radioisotopes/pharmacokinetics , Male , Mice , Oxadiazoles/blood , Rats , Tissue Distribution , Valacyclovir/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...